111317-91-0 Usage
General Description
CONOPRESSIN G is a synthetic analog of vasopressin, which is a hormone that helps regulate water balance in the body. It acts as a vasopressin receptor agonist, meaning it activates the vasopressin receptors in the body. CONOPRESSIN G is used in medical research to study the effects of vasopressin on various physiological processes, such as blood pressure regulation, kidney function, and fluid balance. It has also been used in animal studies to investigate its potential therapeutic effects on conditions such as diabetes insipidus, hypotension, and septic shock. CONOPRESSIN G is not currently approved for clinical use in humans, but it continues to be studied for its potential therapeutic applications.
Check Digit Verification of cas no
The CAS Registry Mumber 111317-91-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,1,3,1 and 7 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 111317-91:
(8*1)+(7*1)+(6*1)+(5*3)+(4*1)+(3*7)+(2*9)+(1*1)=80
80 % 10 = 0
So 111317-91-0 is a valid CAS Registry Number.
InChI:InChI=1/C44H71N15O10S2/c1-3-24(2)35-42(68)54-28(14-9-17-51-44(49)50)38(64)56-30(20-33(47)60)39(65)57-31(23-71-70-22-26(46)36(62)55-29(40(66)58-35)19-25-11-5-4-6-12-25)43(69)59-18-10-15-32(59)41(67)53-27(13-7-8-16-45)37(63)52-21-34(48)61/h4-6,11-12,24,26-32,35H,3,7-10,13-23,45-46H2,1-2H3,(H2,47,60)(H2,48,61)(H,52,63)(H,53,67)(H,54,68)(H,55,62)(H,56,64)(H,57,65)(H,58,66)(H4,49,50,51)/t24-,26-,27-,28-,29-,30-,31-,32-,35?/m0/s1
111317-91-0Relevant articles and documents
Exploiting the MeDbz Linker To Generate Protected or Unprotected C-Terminally Modified Peptides
Arbour, Christine A.,Saraha, Hasina Y.,McMillan, Timothy F.,Stockdill, Jennifer L.
, p. 12484 - 12488 (2017)
C-terminally modified peptides are important targets for pharmaceutical and biochemical applications. Known methods for C-terminal diversification are limited mainly in terms of the scope of accessible modifications or by epimerization of the C-terminal amino acid. In this work, we present a broadly applicable approach that enables access to a variety of C-terminally functionalized peptides in either protected or unprotected form. This chemistry proceeds without epimerization of C-terminal Ala and tolerates nucleophiles of varying nucleophilicity. Finally, unprotected peptides bearing nucleophilic side chain groups can be selectively functionalized by strong nucleophiles, whereas macrocyclization is observed for weaker nucleophiles. The potential utility of this method is demonstrated through the divergent synthesis of the conotoxin conopressin G and GLP-1(7-36) and analogs.
